Description
Tiloron Pharmacodynamics
Low-molecular synthetic inducer of interferon, stimulating the formation of interferon alpha, beta, gamma and lambda in the body. The main producers of interferon in response to tiloron administration are intestinal epithelial cells, hepatocytes, T-lymphocytes, neutrophils and granulocytes. After oral administration the maximum production of interferon is determined in the sequence intestine – liver – blood in 4-24 hours. Tiloron has immunomodulatory and antiviral effects. After a single oral administration of Tiloron at a dose equivalent to the maximum daily dose for humans, the maximum concentration in the lung tissue of interferon lambda was determined after 24 hours, interferon alpha – after 48 hours. Induction of interferon lambda in the lung tissue contributes to an increase in the antiviral protection of the respiratory tract during influenza and other respiratory viral infections. In human leukocytes induces the synthesis of interferon. It stimulates bone marrow stem cells, and, depending on the dose, enhances antibody production, reduces the degree of immunosuppression, restores the ratio of T-suppressors and T-helpers. Effective against various viral infections, including influenza viruses, other acute respiratory viral infections, hepatitis viruses and herpesviruses. The mechanism of antiviral action is associated with inhibition of translation of virus-specific proteins in infected cells, resulting in suppression of virus reproduction.
Indications
As part of complex therapy:
In children from 7 to 18 years:
– Treatment of influenza and other acute respiratory viral infections (ARI).
In adults:
– Treatment of influenza and other acute respiratory viral infections;
– Treatment of herpetic infections. Prevention of influenza and other acute respiratory viral infections in adults
Contraindications
– Hypersensitivity to Tyloron and other components of the drug.
– Pregnancy and lactation
– Childhood age under 7 years old.
– hereditary lactose intolerance, lactase deficiency, glucose-galactose malabsorption.
Caution: As part of the complex therapy of infectious-allergic and viral encephalomyelitis, the drug is used under medical supervision.
Administration during pregnancy and lactation
The drug is contraindicated during pregnancy. If it is necessary to prescribe the drug during lactation, breastfeeding must be stopped.
Dosage and administration
- Tiloron is taken orally, after a meal.
- For children from 7 to 18 years of age:
- In uncomplicated forms of influenza and other acute respiratory infections – 60 mg once a day
- On the 1st, 2nd and 4th day after the treatment start. The course dose is 180 mg (3 tablets).
- For adults:
- For treatment of influenza and other acute respiratory infections – 125 mg per day for the first 2 days of treatment, then 125 mg every 48 hours. For a course of 750 mg (6 tablets). For the prevention of flu and other acute respiratory infections – 125 mg once a week for 6 weeks. For the course – 750 mg (6 tablets).
- For the treatment of herpetic infection – the first two days with 125 mg, then after 48 hours with 125 mg. The course dose is 1.25-2.5 g (10-20 tablets).
- When treating influenza and other acute respiratory infections, if symptoms persist for more than 4 days, consult a physician.
